Stanley Erck - BioCryst Pharmaceuticals Independent Director

BCRX Stock  USD 5.08  0.07  1.36%   

Director

Mr. Stanley C. Erck is no longer Independent Director of Biocryst Pharmaceuticals Inc effective December 3, 2018. Mr. Erck has over 30 years of executive leadership experience in the pharmaceutical industry. Mr. Erck has served as President, CEO and Director of Novavax, Inc., a publicly traded biopharmaceutical company since 2011, having previously served as Executive Chairman from 2010 to 2011, and he has served as a director of Novavax since 2009. From 2000 through 2008, Mr. Erck served as President and Chief Executive Officer of Iomai Corporationrationration, a biopharmaceutical company, leading the company through an initial public offering and a merger with Intercell AG, an Austrian vaccine company, and through the development of a latestage infectious disease product candidate. Prior to Iomai, Mr. Erck served as President and Chief Executive Officer of Procept, Inc., a publicly traded immunology company as Vice President, Corporationrationrate Development at Integrated Genetics Inc., and in management positions within Baxter International Inc. In addition to Novavax, Mr. Erck currently sits on the Board of Directors of MaxCyte, Inc. He received his undergraduate degree from the University of Illinois and his MBA from the University of Chicago Graduate School of Business since 2008.
Age 69
Tenure 16 years
Address 4505 Emperor Boulevard, Durham, NC, United States, 27703
Phone919 859 1302
Webhttps://www.biocryst.com
Erck’s executive experience in the biotech industry and his management positions with major pharmaceutical companies, including his experience with latestage product candidate development, provide an excellent background for service on the Board.

BioCryst Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.1157) % which means that it has lost $0.1157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.2537) %, meaning that it created substantial loss on money invested by shareholders. BioCryst Pharmaceuticals' management efficiency ratios could be used to measure how well BioCryst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.52 in 2024, whereas Return On Capital Employed is likely to drop (0.30) in 2024. At this time, BioCryst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 24.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 7.6 M in 2024.
The company currently holds 848.71 M in liabilities with Debt to Equity (D/E) ratio of 2.4, implying the company greatly relies on financing operations through barrowing. BioCryst Pharmaceuticals has a current ratio of 5.09, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist BioCryst Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, BioCryst Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioCryst Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioCryst to invest in growth at high rates of return. When we think about BioCryst Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Muneaki FujimotoJapan Tobacco ADR
N/A
Michael RoncaSuperior Drilling Products
63
Jay MargolisBoston Beer
66
Roberto BonattiTenaris SA ADR
70
Goichi MatsudaJapan Tobacco ADR
N/A
Yukiko NagashimaJapan Tobacco ADR
57
Louis VachonMolson Coors Brewing
57
Monica TiubaTenaris SA ADR
41
Yves SpeeckaertTenaris SA ADR
59
Betty DeVitaMolson Coors Brewing
57
David FialkowBoston Beer
59
Terence CryanSuperior Drilling Products
53
Sanford RileyMolson Coors Brewing
64
Jaime PucheTenaris SA ADR
69
Amadeo VazquezTenaris SA ADR
77
Hugh RileyMolson Coors Brewing
70
Masahiko SatoJapan Tobacco ADR
N/A
Giovanni SardagnaTenaris SA ADR
N/A
Charles HeringtonMolson Coors Brewing
60
Carlos CondorelliTenaris SA ADR
68
Robert IversenSuperior Drilling Products
62
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Biocryst Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 358 people. BioCryst Pharmaceuticals (BCRX) is traded on NASDAQ Exchange in USA. It is located in 4505 Emperor Boulevard, Durham, NC, United States, 27703 and employs 536 people. BioCryst Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

BioCryst Pharmaceuticals Leadership Team

Elected by the shareholders, the BioCryst Pharmaceuticals' board of directors comprises two types of representatives: BioCryst Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioCryst. The board's role is to monitor BioCryst Pharmaceuticals' management team and ensure that shareholders' interests are well served. BioCryst Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioCryst Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Rob Bennett, Vice President Investor Relations & Operations
Alane Barnes, VP, General Counsel and Corporate Secretary
Elliott Berger, VP Affairs
Stanley Erck, Independent Director
Robert Ingram, Director
William MBBS, Chief Officer
Stephanie Angelini, Chief Officer
Charles Sanders, Independent Director
Jon Stonehouse, CEO and President and Executive Director
Charles Gayer, Senior Officer
Kenneth Lee, Independent Director
Stephen Aselage, Director
William Sheridan, Senior Vice President Chief Medical Officer
Nancy Hutson, Independent Director
Yarlagadda Babu, Sr. VP of Drug Discovery
Fred Cohen, Director
George Abercrombie, Non-Executive Independent Chairman of the Board
Thomas Staab, CFO, Senior Vice President Principal Accounting Officer, Treasurer
Michael Jones, Executive Officer
Lynne Powell, Senior Vice President Chief Commercial Officer
John Bluth, IR Contact Officer
Megan Sniecinski, Chief Business Officer
Sanj Patel, Director
Theresa Heggie, Director
Anthony Doyle, Senior CFO
MD FAAP, Chief Officer

BioCryst Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioCryst Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

BioCryst Pharmaceuticals Investors Sentiment

The influence of BioCryst Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in BioCryst. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to BioCryst Pharmaceuticals' public news can be used to forecast risks associated with an investment in BioCryst. The trend in average sentiment can be used to explain how an investor holding BioCryst can time the market purely based on public headlines and social activities around BioCryst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BioCryst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BioCryst Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average BioCryst Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on BioCryst Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioCryst Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioCryst Pharmaceuticals' short interest history, or implied volatility extrapolated from BioCryst Pharmaceuticals options trading.

Pair Trading with BioCryst Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with BioCryst Stock

  0.62MBRX Moleculin Biotech Financial Report 9th of May 2024 PairCorr
  0.77MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against BioCryst Stock

  0.55MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.54MDWD Mediwound Downward RallyPairCorr
  0.45EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.41CLVRW Clever Leaves HoldingsPairCorr
The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.
The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether BioCryst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioCryst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocryst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocryst Pharmaceuticals Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for BioCryst Stock analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.18)
Revenue Per Share
1.724
Quarterly Revenue Growth
0.174
Return On Assets
(0.12)
Return On Equity
(19.25)
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.